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A simple, sensitive and matrix effect free analytical method for simultaneous determination of 27 
Cd, Hg and Pb in drug samples (i.e., commercial dosage tablets) by inductively coupled plasma 28 
optical emission spectrometry (ICP OES) has been developed. According to the United States 29 
Pharmacopoeia (USP) Chapter 232, those metals are considered elemental impurities from class 30 
1 and they must be assessed in pharmaceutical production as well as in quality control 31 
evaluation. In order to increase the sensitivity of the analysis, a dispersive liquid-liquid 32 
microextraction (DLLME) was performed and seven factors affecting analyte extraction were 33 
optimized by multivariate analysis. The microvolume of  analyte enriched phase was directly 34 
introduced into the plasma using a multinebulizer, providing a high enrichment factor. When 35 
compared to conventional ICP OES analysis, DLLME improves limits of quantitation (LOQ) 36 
values on average 40-fold for all analytes. Consequently, LOQ values were significantly lower 37 
than their permissible daily exposures for oral drugs. Accuracy was evaluated by addition and 38 
recovery experiments following USP recommendations in eight commercial drug samples. 39 
Recovery and RSD values were within the range of 90-108% and 1-9%, respectively.  40 
 41 
Keywords Inductively coupled plasma optical emission spectrometry; Microwave-assisted 42 








1. Introduction 49 
In the pharmaceutical field, safety and efficacy of medicines are fundamental issues. On 50 
this matter, the monitoring of elemental impurities provide assurance of the quality of 51 
pharmaceuticals products since some elements can possess unwanted pharmacological–52 
toxicological effects 1–3. For this purpose, two guidelines have been recently recommended by 53 
the United States Pharmacopeia (USP): (i) Chapter 232, Elemental Impurities Limits 4,  and (ii) 54 
Chapter 233, Elemental Impurities Procedures 5. Chapter 232 specifies 24 elemental impurities 55 
and their toxicity limits considering the oral permissible daily exposure (PDE) values of three 56 
drug categories (i.e., oral, parenteral and inhalation drugs) 4. Chapter 233 describes analytical 57 
procedures for elemental determination using two spectroanalytical methods: inductively 58 
coupled plasma optical emission spectrometry (ICP OES) or inductively coupled plasma mass 59 
spectrometry (ICP-MS) 5.  60 
Although the drafting process of these two chapters started in 2010, a new version of the 61 
general Chapter 232  in a strict compliance with the International Council for Harmonization of 62 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH Q3DR1)  63 
guideline 6,7 was published in 2016 8, became official one year later 9 and was only implemented 64 
in 2018. According to ICH and USP requirements 4–6 the PDE values for elemental impurities 65 
(target elements) are grouped into four main categories: class 1 (Cd, Pb, As, Hg), class 2A (Co, 66 
V, Ni), class 2B (Tl, Au, Pd, Ir, Os, Rh, Ru, Se, Ag, Pt), and class 3 (Li, Sb, Ba, Mo, Cu, Sn, Cr). 67 
These categories are based on the toxicity of target elements, their likelihood of occurrence and 68 
route of administration. Chapter 232 4 and ICH 6 also provide guidance on which of those 24 69 
elemental impurities must be tested for. 70 
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The elements from class 1 are considered toxic to humans and have limited or no use in the 71 
manufacture of pharmaceuticals. Their presence in pharmaceuticals typically comes from 72 
commonly raw materials and must be evaluated in all finished pharmaceutical products and in 73 
potential sources of contamination, for instance active pharmaceutical ingredients and excipients 74 
1–3,6. Even at low concentration levels, the heavy metals Cd, Hg and Pb pose a serious health risk 75 
when used for pharmaceutical purposes 3,6,10,11. Cadmium in their inorganic forms are considered 76 
carcinogenic to humans 12 and, although Hg and Pb are not classified as carcinogenic, these 77 
elements may cause severe toxicological and hematopoietic effects 10–12. Due to their high 78 
toxicity, low PDE values are recommended for these target elements 4,5. 79 
ICP based methods enable fast multi-elemental analysis with high sensitivity, accuracy and 80 
robustness 13–15. On one hand, considering the low PDE values recommended for the above-81 
mentioned elements, the majority of the proposed ICP based methods for elemental impurities 82 
determination are focused on ICP-MS analysis 1–3,15. On the other hand, ICP OES should be 83 
considered a suitable analytical method for this purpose since its higher availability, in contrast 84 
to the higher instrumentation cost of ICP-MS. In order to reach enough sensitivity for 85 
determination of these elements in drug samples using ICP OES, a preconcentration step prior to 86 
measurement could be used 16,17.  87 
On this regard, preconcentration approaches based on microextraction techniques, 88 
particularly dispersive liquid-liquid microextraction (DLLME), have been extensively used since 89 
their advantages, including simplicity, speed, ease of use, low cost and high enrichment factors 90 
using an extremely low extractant solvent volume 17–19. Traditional DLLME involves the use of a 91 
mixture of solvents (i.e., extractant and disperser solvents) which are injected into the aqueous 92 
sample forming a cloudy solution. The dispersion of extraction solvent accelerates the analyte 93 
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extraction and after a centrifugation step is possible to collect an aliquot of the enriched 94 
extractant 18–20. In order to eliminate the disperser solvent and to enhance the extractant phase 95 
dispersion, vortex-assisted DLLME has been employed 18. 96 
After the DLLME procedure, the low extractant solvent volume is generally dissolved in 97 
another miscible organic solvent before the introduction of extract using pneumatic nebulization, 98 
nevertheless, this step can deteriorate the enrichment factor achieved during the 99 
preconcentration. Moreover, the introduction of organic matrices into the argon plasma can cause 100 
severe matrix effects and also the formation of carbon deposits on the plasma torch. In order to 101 
address these challenges, a multinebulizer has been successfully used for the simultaneous 102 
introduction of organic and aqueous solutions for preventing the formation of carbon deposits 21–103 
24. This novel multinebulizer incorporates two independent liquid inlets into a single nebulization 104 
body with a common nebulization gas inlet and a unique outlet orifice allowing that two liquids, 105 
miscible or immiscible, be mixed at the tip of the nebulizer 24. Hence, a microvolume of analyte 106 
enriched extract (without further dilution) and aqueous solution can be simultaneously 107 
introduced into the plasma by independent channels, reducing carbon deposits on the torch 108 
without decreasing the enrichment factor.  109 
To our knowledge, this is the first report which an extraction methodology is applied for 110 
drug samples to elemental impurities determination in accordance with ICH guidelines and USP 111 
chapters. It is well-known that ICP-MS afford suitable sensitivity for the ultratrace determination 112 
of the elemental impurities. However, given the larger number of laboratories that already 113 
employ ICP OES, this study aimed to develop a simple DLLME procedure for the simultaneous 114 




2. Experimental 117 
2.1. Reagents and standard solutions 118 
To minimize contamination all laboratory glassware were kept in 10% v v-1 nitric acid 119 
solution for 24 h and then washed with ultrapure water before use. Experiments were performed 120 
using concentrated high purity grade HNO3 (Merck, Darmstadt, Germany) and ultrapure water, 121 
resistivity higher than 18.2 MΩ cm, (Millipak-40 Filter Unit 0.22 mm NPT, Bedford, MA, 122 
USA). Sodium diethyldithiocarbamate (DDTC, 99%, Sigma-Aldrich, Steinheim, Germany) was 123 
used as complexing agent. Buffer solutions were prepared by dissolving the appropriate amount 124 
of sodium acetate (Panreac Químicas S.A., Castellar del Vallés, Spain) at pH 4 and 6 and sodium 125 
phosphate (Scharlau, Barcelona, Spain) at pH 9. Toluene (99.9%, Sigma Aldrich) and 1-octanol 126 
(99.9%, Sigma Aldrich) were used as extracting solvent. Analytical reference solutions used for 127 
ICP OES calibrations and for addition and recovery experiments were prepared by appropriate 128 
dilutions of 1000 mg L-1 of Cd, Hg and Pb (High Purity Standards, Charleston, SC, USA) in 0.14 129 
mol L-1 HNO3 medium.  130 
 131 
2.2. Instrumentation 132 
A pHmeter (Crison Instrument, Barcelona, Spain) with a combined glass electrode was 133 
used for pH measurements. A centrifuge (model 2690/5, Nahita Centrifuges, Beriain, Spain) was 134 
used to accelerate the phase separation. Experiments were performed using an Agilent 720-ES 135 
inductively coupled plasma optical emission spectrometer (Agilent Technologies, Melbourne, 136 
Australia) operating in axial viewing mode. Argon (99.9992%, Carburos Metálicos S.A, 137 
Barcelona, Spain) was used in all measurements. Plasma operating conditions used in ICP OES 138 
are shown in Table 1.  139 
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Introduction of extract (i.e., analyte enriched phase) were performed using a multinebulizer 140 
(MultiNeb®, Ingeniatrics, Seville, Spain) 24. This multinebulization device is an advanced 141 
version of another previous prototypes already described 25. It presents two independent liquid 142 
inlets and two different types of peristaltic tubes were used depending on the solution introduced. 143 
In the liquid inlet where the analyte enriched phase was introduced, a peristaltic tube compatible 144 
with most petroleum-based products (F-4040-A, id. 0.25 mm, Ismatec, Switzerland) was used. In 145 
the other one where an ultrapure water was continuously pumped, a Tygon® peristaltic tubes (R-146 
3607, id. 0.76 mm, Ismatec) was employed. During the optimization, standard solutions 147 
containing 500 µg L-1 (concentration within the linear range) of Cd, Hg and Pb were used. 148 
NemrodW statistical software (NemrodW® v.2007/2010, LPRAI, Marseille, France) was used to 149 
construct the experimental designs and evaluate the results. 150 
 151 
2.3. Samples and sample preparation  152 
Eight drug samples in solid dosage form (A-H) were analyzed: A) metformin 153 
hydrochloride, used for diabetes treatment; B) losartan potassium, used for hypertension 154 
treatment; C) orfenadrine citrate, monoidratated dipirone and caffeine anidra, used as muscle 155 
relaxant and analgesic; D) sodium dipyrone, used as analgesic; E) nimesulide, used as anti-156 
inflammatory; F) omeprazole, used for benign (gastric or duodenal) peptic ulcers treatment; G) 157 
levothyroxine sodium, used for thyroid treatment; and H) diclofenac sodium, paracetamol, 158 
carisoprodol and caffeine, used for rheumatism treatment. All analyzed samples were 159 
classificated as oral administration route and were purchased in local pharmacies in São Carlos, 160 
São Paulo, Brazil and in San Vicente del Raspeig, Alicante, Spain. 161 
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Sample preparation for drugs in solid dosage form was performed based on previously 162 
proposed works for microwave-assisted sample digestion 26,27. All samples were ground and 163 
homogenized using pestle and mortar and masses of approximately 500 mg were microwave-164 
assisted digested in triplicate using a volume of 7 mL of 2 mol L-1 HNO3. An Ethos 1 microwave 165 
oven (Milestone, Sorisole, Italy) was used. The heating program was applied in two steps: (1) 15 166 
min to reach 220 °C, (2) 15 min at 220 °C, and (3) an additional 15-min cooling step. A 167 
maximum 1.5 kW of microwave power was applied. Subsequently, digests were diluted to 25 168 
mL with distilled-deionized water (final dilution of 50-fold) after adjusting the pH. The samples 169 
not completely digested were centrifuged for 2 min at 3000 rpm for sedimentation of residual 170 
solids.  171 
 172 
2.4. Dispersive liquid–liquid microextraction procedure 173 
A 8.0 mL aliquot of the digested sample, at pH 6 and DDTC concentration of 1.0% m v-1, 174 
was transferred to 10-mL glass tubes. Then, 100 µL of the extractant solvent (i.e., toluene) was 175 
added, and the mixture was shaken using a vortex shaker for 3 min. After shaking, the solution 176 
was centrifuged at 3000 rpm for 2 min to separate the two phases, with the analyte enriched 177 
phase at the top of the solution. After centrifugation, the analyte enriched phase was at the top of 178 
the solution (a toluene layer) and 80 µL of the organic phase was collected from the glass tube 179 
using a micropipette and directly inserted into the ICP OES without further dilution. During the 180 
organic phase sampling, the toluene layer could be evenly collected separately from the aqueous 181 





2.5. Evaluation of accuracy according to USP requirements 185 
According to the USP Chapter 233 accuracy must be evaluated by addition and recovery 186 
experiments with acceptable recoveries ranging from 70 to 150% of the spiked value at 187 
concentrations ranging from 0.5J to 1.5J values for each target element, considering up to 20% 188 
of repeatability 4,5. In this case, the J value (also named target limit) is the concentration of the 189 
element(s) in µg g-1 of interest at the target limit, appropriately diluted to the working range of 190 
the instrument. Thus, J values were calculated according to oral PDE values specific for each 191 
target element (i.e., 5.0, 30 and 5.0 µg day-1 for Cd, Hg and Pb, respectively) divided by the 192 
maximum daily dose (MDD) and the dilution factor (DF), i.e. J =  PDE/(MDD x DF) 4,5. The 193 
MDD ranged from 0.23 to 10 g day-1 for all samples analyzed. For that, the MDD of 10 g day-1 194 
was adopted for all samples to obtain the minimal J value that can be determined. In this work, 195 
therefore, considering the MDD of 10 g day-1 and the DF of 50 (i.e., 500.0 mg of sample in 25.00 196 
mL), the added concentrations (i.e., 0.5J to 1.5J values) were 5.0 and 15 µg L-1 for Cd and Pb; 197 
and 30 and 90 µg L-1 for Hg. 198 
 199 
3. Results and discussion 200 
3.1. Optimization of dispersive liquid–liquid microextraction 201 
The multivariate optimization of the DLLME procedure was proceeded into two 202 
complementary steps: (i) a Plackett-Burman design was employed as screening approach to 203 
identify between significant and non-significant factors, followed by (ii) a central composite 204 
design (CCD) to obtain optimal values for the significant factors. In both steps, the experiments 205 
were randomly performed in order to nullify the effect of extraneous or nuisance factors using 206 
standard solutions containing 500 µg L-1 of all analytes. Seven factors at two levels were 207 
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evaluated on the Plackett-Burman design. The DLLME variables investigated and their low (-) 208 
and high (+) levels are described in Table 2. The results of the Plackett-Burman design are 209 
visualized using Pareto charts of the standardized effect in Fig. 2. 210 
In the Pareto charts (Fig. 2a-c) the gray bars indicate variables presenting a significant 211 
effect on DLLME procedure, while non-significant factors are indicate by white bars. The bars to 212 
the right indicate a positive effect, i.e., favorable condition at higher values of that factor, while 213 
the opposite effect is indicate by bars to the left. In general, DLLME was favored when using 214 
toluene as extractant solvent at high values of DDTC concentration, extraction time and 215 
centrifuge speed and low centrifugation time. Unfortunately, the use of 1-octanol does not satisfy 216 
the threshold limit established by the USP (data not shown), and therefore, toluene was used as 217 
extractant solvent. Only the factors (1) extractant solvent; (2) extractant solvent volume; and (3) 218 
sample pH showed a significant effect on the Plackett-Burman experiment.  219 
Due to pH influence on the complexation step, its evaluation is indispensable in metal 220 
extraction procedures 28. In case of DDTC, pH values below 3.95 favors the protonated form of 221 
DDTC (pKa = 3.95 29), therefore limiting chelate formation. Moreover, high pH values could 222 
also have a negative effect on extraction, since analytes can form hydroxides decreasing the 223 
amount extracted. In turn, the extractant solvent volume infers directly in the enrichment factor 224 
of the analytes 18,19. By increasing the extractant solvent volume to a certain degree, the 225 
extraction efficiency is increased. However, further increases could cause a dilution effect, 226 
resulting in a decrease in the enrichment factor.  227 
In order to optimize both significant factors, a central composite design (CCD) was 228 
performed. Both factors were investigated at five levels as described in Table 3 and the response 229 
surfaces obtained for the different elements are shown in Fig. 3. Optimum conditions for each 230 
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response surface were calculated and the lowest level of extractant solvent volume was obtained 231 
for all analytes (i.e., 100 μL of toluene) and pH values at 6.1, 6.3 and 5.2 for Cd, Hg and Pb were 232 
obtained, respectively. On that basis pH 6.0 (average of those values) and an extractant solvent 233 
volume of 100 μL were selected as the most favorable conditions for all analytes. In summary, 234 
the optimized conditions for simultaneous DLLME of Cd, Hg and Pb were: DDTC concentration 235 
1.0% m v-1, 100 μL of toluene as extractant solvent, pH 6.0, extraction time of 3 min, 236 
centrifugation time of 2 min and a centrifugation speed of 3000 rpm. 237 
 238 
3.2. Analytical performance for DLLME-ICP OES method according to the USP 239 
requirements 240 
The proposed microextraction procedure provided a significant increase in sensitivity for 241 
all elements. Table 4 summarizes the analytical figures of merit of the developed DLLME-ICP 242 
OES method and conventional ICP OES analysis for determination of Cd, Hg and Pb in drug 243 
samples. Coupling DLLME to ICP OES is particularly challenging due to spectral and non-244 
spectral interferences caused by organic solvents 17–19. On this regard, in the multinebulization 245 
device used, water is continuously introduced into the plasma. This advantage over conventional 246 
nebulization system facilitates the introduction of organic solvents that are not so compatible 247 
with plasma, avoiding the need of continuous cleaning of torch and injector tube 21,24. 248 
 249 
3.2.1. Linearity, sensitivity and precision 250 
Two calibration curves were performed: (i) conventional ICP OES analysis (i.e., without 251 
DLLME procedure) using five calibration points with working range from 1.0 to 5.0 mg L-1 for 252 
all analytes, and (ii) DLLME-ICP OES using seven calibration points with working range from 253 
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2.5 to 120 µg L-1 for Cd, Hg and Pb. According to the USP Chapter 233, measurement of at least 254 
three calibration standards in the working range between 0.3J and at least 1.5J for each target 255 
element are recommended 5. In case of the developed analytical method, the working range was 256 
set from 0.25J to 2.0J for simultaneous determination of Cd, Hg and Pb. The correlation 257 
coefficients (r) obtained for all DLLME-ICP OES calibration curves ranged from 0.9980 to 258 
0.9996, showing good linearity. The enrichment factor (EF) values for each analyte were 259 
calculated as the ratio between sensitivity values with and without DLLME procedure. High EF 260 
values were obtained, ranging from 55 to 72.  261 
The repeatability was estimated from six independent measurements of samples spiked at 262 
0.5J and 1.5J of each target element. The relative standard deviations obtained were ranged from 263 
1.6 to 5%. Obtained repeatability values were significantly lower than 20% of RSD stated by the 264 
USP Chapter 233 for repeatability 5. 265 
 266 
3.2.2. Limits of detection and quantification 267 
Limits of detection (LOD) and quantification (LOQ) were calculated according to 268 
Eurachem guidelines30 considering the analyte concentration corresponding to the obtained 269 
standard deviation (i.e., determined by 10 consecutive measurements of the blank) at low levels 270 
multiplied by a factor k. The IUPAC default value for k is 10 and 3 for LOQ and LOD, 271 
respectively. The LOQ values for conventional ICP OES analysis were all higher than the target-272 
limits. In turn, the LOQ values for Cd, Hg and Pb using DLLME are 36, 33 and 6-times, 273 
respectively, lower than their respective J values. This means a LOQ improvement on average 274 
24-fold. Following USP recommendations, LOQ values ≤0.3J are suggested as acceptance 275 
criteria 5. Once LOQ values achieved for Cd, Hg and Pb were 11, 10 and 2-times lower than their 276 
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0.3J, respectively, it may be inferred that the proposed DLLME-ICP OES method is suitable to 277 
meet USP requirements even using drugs in tablets form with MDD higher than 10 g day-1. 278 
Taking into account the low target limits for elements from class 1 4,6, Table 5 summarizes 279 
analytical methodology previously reported for Cd, Hg and Pb determination in pharmaceutical 280 
samples using ICP OES. Considering MDD of 10 g day-1, the LOQ values obtained for Cd 281 
26,31,32, Hg 26 and Pb 26,31–33 were higher than 0.3J (i.e., LOQ established by USP). As it can be 282 
noted, none of the aforementioned analytical methods meet the USP requirements for these three 283 
analytes at the same time. There are only two analytical methods with comparable LOQ values 284 
34,35. In the first work 34, the low LOQ values were achieved using a dilution factor lower than 285 
30-fold. Generally for conventional sample introduction by pneumatic nebulization using ICP 286 
OES, maximum total dissolved solids recommended is lower than 1% m v-1 13. In addition, the 287 
low dilution factor can induce severe matrix effects, and therefore, effects on aerosol transport 288 
and plasma properties should be carefully assessed 13. In the second study 35, the authors used an 289 
ultrasonic nebulizer with a relative high sample consumption (i.e., 1.9 mL min-1), being the main 290 
disadvantage the high cost of the ultrasonic nebulizer.  291 
 292 
3.2.3. Accuracy 293 
The trueness was evaluated by addition and recovery experiments performed taking into 294 
account J values as USP Chapter 233 recommendation 5. All samples were spiked at levels 295 
equivalent to 0.5J and 1.5J for Cd, Hg and Pb in order to check the trueness of the method (Table 296 
6). All analytes were below their respective LOQ values for all samples analyzed. This pattern 297 
was also observed in previous studies with commercial drug samples in solid dosage form 298 
26,27,31,33–35. Consequently, all samples are within the limits recommended by the USP Chapter 299 
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232 taking into account the maximum daily dose of each medicine as indicated in the package 300 
insert, i.e., lower than 10 g day-1 for tablets drugs. Recovery values ranged from 90 to 108% 301 
were observed by spike experiments at both levels based on acceptable recoveries established 302 
from 70 to 150% 5. No matrix effects were observed for DLLME-ICP OES measurements and 303 
the repeatability was demonstrated by a precision ≤9% RSD (n = 3) considering all samples.  304 
 305 
4. Conclusions 306 
The developed DLLME procedure combined with ICP OES was successfully applied to 307 
the simultaneous extraction/preconcentration of Cd, Hg and Pb for trace determination of the 308 
above-mentioned elements using ICP OES after a microwave-assisted acid digestion of drug 309 
samples using dilute nitric acid. Analytical performance was well validated in the terms of 310 
linearity, LOQ, repeatability, and accuracy in accordance with the USP Chapter 233. 311 
Pharmaceutical sample preparation using dilute nitric acid solutions provide safer operation and 312 
reduced acid consumption. Posteriorly, DLLME affords high enrichment factors, simplicity and 313 
sustainability once reagents requirements and waste generation are extremely minimized. When 314 
compared with conventional ICP OES analysis, DLLME-ICP OES affords a significant increase 315 
of sensitivity showing an enrichment factor on average of 65-fold. Consequently, considering the 316 
benefits of direct analysis of organic phase using a multinebulization based system and the 317 
appropriate multivariate optimization of DLLME, suitable sensitivity to follow USP 318 
requirements for determination of Cd, Hg and Pb using ICP OES was achieved. Therefore, 319 
DLLME-ICP OES methods can be seen as a promising alternative for trace elemental analysis in 320 
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Fig. 2 Pareto charts obtained in the screening study of the experimental variables affecting the 436 
DLLME of (a) Cd, (b) Hg and (c) Pb. (■) significant effect; (□) insignificant effect. Analyte 437 



















Fig. 3 Response surface from central composite design for (a) Cd, (b) Hg and (c) Pb. Analyte 455 









Table 1 Operating parameters used in Agilent 720-ES ICP OES 463 
Instrument parameter Value 
RF applied power (kW) 1.2 
Plasma gas flow rate (L min-1) 15 
Auxiliary gas flow rate (L min-1) 1.5 
Nebulizer gas flow rate (L min-1) 0.75 
Organic extract uptake rate (µL min-1) 50 
Aqueous solution uptake rate (µL min-1) 200 
Nebulizer MultiNeb® 
Spray chamber Cyclonic spray chamber 
Number of replicates 3 
Analytes Emission line (nm)a 
Cd 226.502 II 
Hg 253.652 I 
Pb 220.353 II 
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Table 2 Factors and levels of the Plackett-Burman design 475 
Factor 
Level 
Low (-) High (+) 
Extractant solvent 1-octanol toluene 
 Extractant solvent volume (µL) 100 200 
 Sample pH 4 9 
DDTC concentration (% m v-1) 0.5 1 
Extraction time (min) 1 3 
Centrifugation time (min) 2 4 






















Table 3 Factors and levels of the central composite design 495 
Factor 
Level Star points (α = 1.41) 
Low (-) Central (0) High (+)  -α +α  
 Extractant solvent volume (µL) 115 150 185 100 200 























Table 4 Analytical figures of merit for Cd, Hg and Pb determination using DLLME-ICP OES 516 
and conventional ICP OES analysis 517 
 
Emission line (nm) 
 
Cd (226.502) Hg (253.652) Pb (220.353) 
ICP OES 
   
Linear range (µg L-1) 1000 - 5000 1000 - 5000 1000 - 5000 
ra 0.9994 0.9990 0.9994 
Sensitivity (cps L μg-1)b 10.85 ± 0.14 0.99 ± 0.02 0.455 ± 0.006 
LOD (µg L-1) 4 20 20 
LOQ (µg L-1) 12 70 70 
DLLME-ICP OES 
   
Linear range (µg L-1) 2.50 - 120 2.50 - 120 2.50 - 120 
rc 0.9996 0.9994 0.9980 
Sensitivity (cps L μg-1)b 734 ± 11 54.4 ± 1.0 32.6 ± 0.7 
EFd 68 ± 2 55 ± 2 72 ± 2 
LOQ (µ L-1) 0.3 1.8 1.6 
USP LOQ ≤0.3J (µg L-1) ≤3 ≤18 ≤3 
Repeatability 0.5J (RSD%)e 1.6 5 4 
Repeatability 1.5J (RSD%)f 4 3 4 
 518 
a Correlation coefficient (five calibration points). 519 
b Slope ± standard deviation. 520 
c Correlation coefficient (seven calibration points). 521 
d Enrichment factor ± expanded uncertainty. Calculated as slope ratio between calibration curves with and 522 
without DLLME.  523 
e Mean value for six replicate analyses of spiked solution with 5.0, 30 and 5.0 µg L-1 of  Cd, Hg and Pb, 524 
respectively.  525 
f Mean value for six replicate analyses of spiked solution with 15, 90 and 15 µg L-1 of  Cd, Hg and Pb, 526 
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(μg L-1) Reference 
Cd Hg Pb 
Pills and tablets 500 MW-ADb 
7 mL of 2 mol L-1 HNO3; final digest 
volume of 50 mL 




5 mL of 14 mol L-1 HNO3 + 1 mL of 
H2O2 30% v v-1; final digest volume 
of 25 mL 
125 4.2 NA 64 31 
Pills and tablets 100 MW-ADb 
5 mL of 3HNO3:1HCl v v-1; final 
digest volume of 50 mL 
500 2.6 10 114 33 
Levetiracetam 1000 MW-ADb 
15 mL of 14 mol L-1 HNO3 + 2 mL of 
H2O2 30% v v-1; final digest volume 
of 25 mL 
25 16 16 4 32 
Lu tablets 450 MW-ADb 
12 mL of 3HNO3:1HCl v v-1; final 
digest volume of 13 mL 




7 mL of 14 mol L-1 HNO3 + 2 mL of 
HCl + 1 mL of H2O2 30% v v-1; final 
digest volume of 50 mL 
250 0.4 1.2 0.7 35 
Pills and tablets 500 MW-ADb + DLLME 
7 mL of 2 mol L-1 HNO3; final digest 
volume of 25 mL 
50 0.3 1.8 1.6 
This 
work 
NA: Not applicable.  
a Dilution factor, considering sample mass, final digest volume and further sample dilutions before analysis.  
b Microwave-assisted digestion in closed vessel. 






Table 6 Found concentrations (mean ± standard deviation, µg L-1, n = 3) and recovery values in 
parenthesis (mean ± RSD, %) obtained for the spiked in digested drug samples (A-H) according 






Cd Hg Pb 
A 
0.5J 5.0 ± 0.2 (98 ± 2) 31 ± 2 (102 ± 5) 5.0 ± 0.3 (99 ± 6) 
1.5J 14.9 ± 0.7 (98 ± 4) 95 ± 3 (105 ± 4) 15.3 ± 0.9 (102 ± 6) 
B 
0.5J 5.2 ± 0.1 (99 ± 4) 30.3 ± 0.6 (101 ± 2) 4.6 ± 0.2 (91 ± 4) 
1.5J 14.9 ± 0.7 (97 ± 6) 87 ± 3 (97 ± 3) 14 ± 1 (91 ± 8) 
C 
0.5J 5.1 ± 0.3 (98 ± 2) 30 ± 2 (99 ± 8) 4.5 ± 0.3 (90 ± 6) 
1.5J 14.3 ± 0.9 (94 ± 7) 88 ± 7 (98 ± 7) 13.7 ± 0.8 (91 ± 5) 
D 
0.5J 5.0 ± 0.3 (100 ± 6) 29 ± 2 (95 ± 6) 5.2 ± 0.3 (103 ± 7) 
1.5J 15 ± 1 (100 ± 9) 85 ± 4 (95 ± 4) 15 ± 1 (101 ± 8) 
E 
0.5J 4.8 ± 0.3 (97 ± 6) 32 ± 1 (105 ± 4) 5.40 ± 0.09 (108 ± 2) 
1.5J 16 ± 1 (103 ± 7) 90 ± 7 (100 ± 8) 15 ± 1 (102 ± 9) 
F 
0.5J 5.0 ± 0.3 (99 ± 6) 30 ± 2 (100 ± 7) 5.0 ± 0.2 (101 ± 4) 
1.5J 15 ± 1 (98 ± 6) 93 ± 6 (104 ± 6) 14.9 ± 0.6 (99 ± 4) 
G 
0.5J 4.8 ± 0.1 (96 ± 3) 31 ± 2 (103 ± 6) 4.8 ± 0.2 (95 ± 3) 
1.5J 16.0 ± 0.1 (106 ± 1) 96 ± 2 (107 ± 3) 14.7 ± 0.8 (98 ± 5) 
H 
0.5J 5.13 ± 0.06 (103 ± 1) 29 ± 2 (98 ± 8) 5.0 ± 0.3 (99 ± 5) 
1.5J 15.4 ± 0.9 (103 ± 6) 88 ± 5 (97 ± 5) 14.7 ± 0.2 (98 ± 2) 
0.5J: Spiked digest with 5.0, 30 and 5.0 µg L-1 of  Cd, Hg and Pb, respectively.  
1.5J: Spiked digest with 15, 90 and 15 µg L-1 of  Cd, Hg and Pb, respectively.  
 
